Deals channel feed

Ab­b­Vie hands back head­line drug in $63B Al­ler­gan buy­out to Mol­e­c­u­lar Part­ners af­ter FDA re­jec­tion. What's next?

4 years ago
Pharma

Bi­o­Life So­lu­tions sets up shop in In­di­anapo­lis, adding a slate of new cell and gene ther­a­py tools to its belt

4 years ago
Cell/Gene Tx
Manufacturing

Robert Baze­more inks one last deal for Epizyme — adding Chi­na to Tazverik's glob­al blue­print — be­fore head­ing out from CEO of­fice

4 years ago
China

Philip Mor­ris bags an­oth­er biotech as bid­ding war with Car­lyle over Vec­tura deal heats up

4 years ago

Drug pric­ing dis­rup­tor EQRx makes the big leagues with $1.8B SPAC deal and a new CEO at the helm

4 years ago
Financing

Chi­nese start­up with Mer­ck vet at the helm ac­quires rights to Oys­ter Point's eye dis­ease nasal spray

4 years ago
China

mGx M&A? Mod­er­na ex­ecs are lever­ag­ing their Covid cash on gene edit­ing, gene ther­a­py deals

4 years ago
Bioregnum

With an as­sist from As­traZeneca, the sal­vage crew at Sier­ra bets an­oth­er $216M they can res­ur­rect an old Gilead JAK drug

4 years ago

Gilead’s Kite jumps back to the bar­gain­ing ta­ble to forge $875M pact with a new­ly-emerged up­start on next-gen cell ther­a­pies

4 years ago

Bay­er nabs star biotech Vi­vid­ion with a $2B buy­out and an ‘arms-length’ pact, pulling a part­ner out of the IPO con­ga line

4 years ago

Soft­Bank claims $5B stake in Roche amid grand plans to in­vest in biotech — re­ports

4 years ago

Saman­tha Du's Zai Lab inks sur­pris­ing re­search col­lab with Schrödinger for DNA dam­age drug

4 years ago
R&D
China

Af­ter strug­gling with its sole drug for years, Mar­i­nus rides pos­i­tive da­ta to a com­mer­cial­iza­tion deal in Eu­rope

4 years ago
FDA+

Sanofi buys mR­NA play­er Trans­late Bio for $3.2B. And the price fits a pop­u­lar range for biotech M&A

4 years ago

Ab­cam brings a long­time col­lab­o­ra­tor in house as part of $340M buy­out pact

4 years ago
Outsourcing

Mod­er­na takes on a low-risk pact with CAR-T play­er Au­to­lus for mR­NA-based can­cer drugs

4 years ago

Roivant bumps stake in Im­muno­vant with a $200M deal. But with M&A off the ta­ble, shares crater

4 years ago

Ipsen con­tin­ues its shop­ping spree with a $1B-plus deal for Ex­i­cure's next-gen oligonu­cleotides

4 years ago

On the heels of Take­da pact, Pep­tiDream kicks off $2.2B deal to broad­en Al­ny­lam's siR­NA de­liv­ery scope

4 years ago

Eli Lil­ly teams up with KRAS drug pi­o­neer Yi Liu tar­get­ing small mol­e­cule I/O with $70M up­front

4 years ago

As­traZeneca castoff draws $123M wa­ger on CX­CR2 an­tag­o­nist as Are­na lines up a buy­out op­tion

4 years ago
Financing

Am­gen bel­lies back up to the M&A ta­ble for an­oth­er biotech buy­out, this time with a $2.5B deal for an an­ti­body play­er fo­cused on PS­MA

4 years ago

Google-backed Cal­i­co dou­bles down on an­ti-ag­ing R&D pact with Ab­b­Vie as part­ners ante up $1B, start to de­tail drug tar­gets

4 years ago
R&D

Look­ing to repli­cate Covid-19 suc­cess in neu­ro, BioN­Tech back­ers bet on AC Im­mune and its new­ly-ac­quired Parkin­son's vac­cine

4 years ago
Financing
First page Previous page 71727374757677 Next page Last page
A service from the Financial Times